Eptanemab
(epratuzumab)Phase 3Monoclonal antibody
UCBEpratuzumab is used to treat systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues, causing inflammation and damage to joints, skin, kidneys, and other organs.[1] Eptanemab is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Eptanemab is one of 233 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
8
Indications
23
Total Trials
0
Active Trials
232
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Eptanemab
UCBPhase 3
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Tafasitamab
IncytePreclinical
PEG-Intron
Merck & Co.Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Stem Cells
KKang Stem Biotech Co., Ltd.
Preclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Preclinical
JY231
SShenzhen Genocury Biotech Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Systemic Lupus Erythematosus12 trials
Show 9 more trials
Lymphoma5 trials
Acute Lymphoblastic Leukemia3 trials
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for epratuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]